Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 41

Results For "therapies"

851 News Found

Pfizer acquires Seagen for US$ 43 billion to battle cancer
News | March 14, 2023

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology


Evonik opens new facility for pharmaceutical lipids in Germany
News | March 09, 2023

Evonik opens new facility for pharmaceutical lipids in Germany

New GMP facility for clinical and small-scale commercial pharmaceutical lipids


AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India
News | March 01, 2023

AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India

Receives regulatory approval for its molecule ‘Selumetinib’ in India


Sanofi reaffirms commitment to rare diseases in India
News | February 28, 2023

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India


AlloVir appoints Derek Adams to Board of Directors
People | February 27, 2023

AlloVir appoints Derek Adams to Board of Directors

Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.


Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform
Biotech | February 27, 2023

Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.


MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates
Diagnostic Center | February 24, 2023

MEI Pharma and Infinity Pharmaceuticals inks merger agreement to advance three promising clinical oncology candidates

Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months


Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940
Drug Approval | February 23, 2023

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial


Merck and AstraZeneca present final results from Phase 3 PROpel Trial
Drug Approval | February 18, 2023

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival


Pfizer announces Talzenna and Xtandi combination data from phase 3 study
News | February 18, 2023

Pfizer announces Talzenna and Xtandi combination data from phase 3 study

Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI